Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(Z)-SU4312 是 MAO-B 和 NOS 的抑制剂(IC50 值分别为 0.2 μM 和 19.0μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,290 | 现货 | ||
2 mg | ¥ 1,930 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,580 | 现货 |
产品描述 | (Z)-SU4312 is a inhibitor of MAO-B and NOS(IC50 value of 0.2 μM, 19.0μM,respectively). |
靶点活性 | MAO-B:0.2μM |
体外活性 | (Z)-SU4312 unexpectedly prevented MPP(+) -induced neuronal apoptosis in vitro and decreased MPTP-induced loss of dopaminergic neurons, reduced expression of mRNA for tyrosine hydroxylase and impaired swimming behaviour in zebrafish.?(Z)-SU4312 exhibited non-competitive inhibition of purified neuronal NOS (nNOS) with an IC(50) value of 19.0?μM but showed little or no effects on inducible and endothelial NOS. Molecular docking simulations suggested an interaction between (Z)-SU4312 and the haem group within the active centre of nNOS[1]. |
体内活性 | (Z)-SU4312 was able to selectively inhibit monoamine oxidase-B (MAO-B) activity both in vitro and in vivo, with an IC50 value of 0.2 μM.(Z)-SU43122 provides therapeutic benefits in cellular and animal models of PD, possibly through multiple mechanisms including enhancement of MEF2D through the activation of PI3-K/Akt pathway, maintenance of mitochondrial biogenesis and inhibition of MAO-B activity.?(Z)-SU4312 thus may be an effective drug candidate for the prevention or even modification of the pathological processes of PD[2]. |
动物实验 | MPP(+) -treated neurons and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated zebrafish were used to study neuroprotection by?(Z)-SU4312. NOS activity was assayed in vitro to examine direct interactions between?SU4312?and NOS isoforms[1]. |
分子量 | 264.32 |
分子式 | C17H16N2O |
CAS No. | 90828-16-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (113.5 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.7833 mL | 18.9165 mL | 37.8329 mL | 94.5823 mL |
5 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL | 18.9165 mL | |
10 mM | 0.3783 mL | 1.8916 mL | 3.7833 mL | 9.4582 mL | |
20 mM | 0.1892 mL | 0.9458 mL | 1.8916 mL | 4.7291 mL | |
50 mM | 0.0757 mL | 0.3783 mL | 0.7567 mL | 1.8916 mL | |
100 mM | 0.0378 mL | 0.1892 mL | 0.3783 mL | 0.9458 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(Z)-SU4312 90828-16-3 Immunology/Inflammation Metabolism Neuroscience MAO NOS (Z)-SU-4312 (Z)SU4312 SU4312 SU 4312 SU-4312 (Z) SU4312 Inhibitor inhibitor inhibit